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Precis: Dasatinib demonstrated no significant anti-sarcoma activity in patients with epithelioid 
sarcoma or solitary fibrous tumor. Patients with alveolar soft part sarcoma had prolonged disease 
progression-free and overall survival but not necessarily caused by dasatinib. A small minority of 
patients with chondrosarcoma or chordoma experienced objective tumor response or prolonged 
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Background: Alveolar soft part sarcoma (ASPS), chondrosarcoma (CS), chordoma, epithelioid 
sarcoma (ES) and solitary fibrous tumor (SFT) are malignant tumors which are relatively 
resistant to chemotherapy for which more effective drug therapy is needed. 
Patients and methods: The five listed subtypes were enrolled into a single “indolent” sarcoma 
cohort in a phase II study of dasatinib using a Bayesian continuous monitoring rule for 
enrollment. The primary objective was to estimate the 6-month progression-free survival (PFS) 
rate using Choi criteria with a target of >50%. Cross-sectional imaging was done prior to start of 
treatment, every 2 months for 6 months and then every 3 months during treatment. Two and 5 
year survival rates were determined. 
Results: 116 patients were enrolled in 45 months and 109 began treatment with dasatinib. The 6-
month PFS rate and median PFS were 48% and 5.8 months, respectively. The rate of PFS at 6 
months was highest in ASPS (62%) and lowest in SFT (30%). More than 10% of patients with 
ASPS, CS or chordoma had stable disease for more than 1 year. Collectively for all 5 sub-types, 
2-year and 5-year overall survival rates were 44% and 13%, respectively. Objective response 
was observed in 18% of patients with CS or chordoma. 
Conclusions: Dasatinib failed to achieve control of sarcoma growth for at least 6 months in more 
than 50% of the patients in this trial using Choi tumor response criteria. Objective tumor 
response and prolonged stable disease was observed in >10% of patients with CS or chordoma. 
 
  
Page 3 of 17 Cancer











Sarcomas are a diverse group of stromal cancers of which the large majority is derived from 
mesodermal tissue. A number of distinct histologic sub-types of sarcoma share the unusual 
behavior of low cell proliferation rate but high risk of local recurrence and systemic spread 
which may occur years after definitive treatment of the primary cancer. The life span of 
individuals with one of these “indolent” sarcomas after development of metastasis is often years. 
For example, the rate of metastases in patients with alveolar soft part sarcoma (ASPS) is greater 
than 50% but median survival is more than 3 years after diagnoses of metastases.
1, 2
  Solitary 
fibrous tumor (SFT) and epithelioid sarcoma (ES) are other soft tissue sarcomas with an indolent 
growth rate but a high propensity for recurrence and metastases.
3, 4
 Chordoma and low to 
intermediate grade chondrosarcoma (CS) are types of sarcoma arising in bone that also exhibit a 
low mitotic rate but have risk of local recurrence and metastases. With few notable exceptions, 
these sarcomas are resistant to chemotherapy, and patients afflicted with one of these sarcomas 
are in great need of more effective drug treatment when the disease cannot be excised and is 
refractory to radiation, or is widely metastatic. Cediranib and sunitinib have activity in ASPS.
5, 6
 
Bevacizumab combined with temozolomide, and sunitinib have activity in SFT.
7, 8
 And imatinib 
has activity in chordoma.
9
 In clinical trials of these drugs to treat ASPS, SFT and chordoma, 
objective responses were observed in a minority of patients but more than 50% of patients were 
surviving free from sarcoma progression 6 months after starting therapy. 
The mechanism of anti-tumor activity of cediranib, sunitinib and imatinib in ASPS, SFT and 
chordoma has not been definitively established to our knowledge. A number of preclinical 
studies suggest that platelet-derived growth factor pathway is active in ASPS, SFT and 
chordoma.
5, 10-12
 The Src pathway is active in chondrosarcoma and inhibition of Src in vitro by 
dasatinib has led to reduced chondrosarcoma viability, reduced cell motility and induced 
apoptosis.
13, 14
 Dasatinib is a small molecule inhibitor of the Src family of kinases, platelet-
derived growth factor receptor alpha and beta, c-KIT, BCR-ABL and ephrin receptor kinases that 
has significant clinical activity in chronic myelogenous leukemia.
15
 We evaluated the clinical 
activity of dasatinib in patients with locally advanced or metastatic ASPS, CS, chordoma, ES or 
SFT because of an unmet need for more effective drug therapy. At the time the trial was 
designed, based on pre-clinical studies and clinical experience with imatinib and sunitinib in 
treatment of sarcoma, we felt there was a reasonable chance for dasatinib to have anti-tumor 
activity in ASPS, CS, chordoma and SFT. Patients with ES were included because of a lack of 
effective drugs against this cancer. 
Patients and Methods 
Study 
We performed a multi-institutional, open-label, single-arm trial of dasatinib in patients with 
advanced sarcoma. We conducted 3 parallel trials focused on different sarcoma histologic types 
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(aggressive sarcoma sub-types, indolent sarcoma sub-types and gastrointestinal stromal tumor) 
under one parent study (SARC009) coordinated by Sarcoma Alliance through Research and 
Collaboration (SARC). Results of dasatinib in patients with aggressive sarcoma sub-types are 
reported elsewhere.
16
 SARC provided central coordination of study conduct, patient enrollment, 
study monitoring and audit. Cancer Research and Biostatistics (www.crab.org) developed and 
maintained an electronic study database. Statistical support was provided by V. Bolejack for the 
indolent sub-type analysis. Bristol-Myers Squibb provided dasatinib and financial support. The 
trial was registered with clinicaltrials.gov (NCT00464620). The study was approved by all 
participating sites’ Institutional Review Boards. 
Patients 
Study enrollment into the “indolent” sub-study was restricted to patients 13 years of age or older 
weighing at least 50 Kg with measurable, ASPS, grade 1 or 2 CS of bone, chordoma, ES or SFT 
that was incurable by conventional treatment. Confirmed disease progression based on standard 
imaging criteria prior to enrollment was not required. Additional eligibility criteria included 
ECOG performance score <2, ability to swallow whole tablets, absolute neutrophil count 
>1,500/ul, platelet count >75,000/ul, serum creatinine <2 times institutional upper limit of 
normal (IULN), prothrombin and partial thromboplastin times <1.5 times IULN, serum 
magnesium, potassium and calcium at least the lower limit of normal range, corrected QT 
interval <450 msec, and left ventricular ejection fraction at least 45%. All patients provided 
written informed consent. Local site investigators determined patient eligibility; however, 
patients’ pathology slides were centrally reviewed and diagnoses were retrospectively confirmed 
for all subjects by the study pathologist (D. R. Lucas) within 2 months of patient enrollment and 
initiation of therapy. 
Study treatment and evaluations 
Dasatinib was started at 100 mg orally twice daily. The study amended the starting dose to 70 mg 
twice daily because of toxicity observed in other trials of dasatinib.
17
 A cycle of treatment was 
28 days. Dose and schedule adjustments were allowed for toxicity to 50 mg twice daily then to 
100 mg once daily. Drug treatment was continued until disease progression by Choi criteria
18
, 
unacceptable toxicity, patient choice or provider decision. The extent of disease was assessed 
using CT or MRI within 2 weeks of treatment, every 2 months for 6 months and then every 3 
months until disease progression was documented in patients remaining on treatment. 
Electrocardiogram was performed during screening and after the first month of treatment. 
Correction of the QT interval was made by local sites’ using Bazett’s formula. Safety evaluations 
included complete blood counts and comprehensive metabolic panel performed monthly for 6 
months, every 6 weeks for the next 6 months and then every 12 weeks during treatment. Adverse 
events were recorded according to Common Terminology Criteria for Adverse Events version 
3.0. 
Page 5 of 17 Cancer










The primary study endpoint was 6-month PFS rate using Choi criteria (10% or greater increase 
in the sum of the greatest dimension without a greater than 15% reduction in the average tumor 
density of target lesions). We chose to assess tumor response using Choi criteria instead of 
RECIST or WHO because improvements in the resolution of cross-sectional imaging allowed for 
more precise tumor measurements such that we felt a change in tumor size of more than 10% 
could be reliably determined and because of prior experience assessing GIST response treated 
with another tyrosine-kinase inhibitor, imatinib.
18
 Secondary endpoints included patient safety 
assessment by adverse event rate, 2 and 4-month PFS rates, median time to progression, 2-year 
and 5-year overall survival rates. Study endpoints were assessed by participating investigators; 
central radiology review was not performed. Patients were censored for PFS at the date of last 
radiology evaluation if progression had not occurred. Patients were censored for survival at the 
date of last contact with survival time calculated from date of registration to death. Patients were 
contacted at least every 12 months for survival until 5 years from registration. 
Statistical methods 
Patients with one of the eligible “indolent” sarcoma sub-types were enrolled into a single cohort 
because of the relative rarity and uncertainty of rate of accrual of each of the sarcoma sub-types 
under study to justify enrollment in sub-type-specific cohorts. The study was designed to 
estimate the PFS and OS for the group. Post hoc analysis was performed on each sarcoma sub-
type. We estimated a 6-month PFS rate of 30-40% for inactive therapies and greater than 50% 
for an active therapy. A Bayesian monitoring rule was used to stop enrollment if the probability 
that the 6-month PFS rate was at least 50% fell to less than .85%. The stopping rule was chosen 
to provide no higher than a 10% chance that the trial would be terminated early if the true 6-
month PFS was >50%. We estimated that the trial would terminate early more than 88% of the 
time with fewer than 30 patients enrolled if the 6-month PFS rate was 30%. A minimum of 10 
and a maximum of 116 patients were to be enrolled. We anticipated an accrual rate of 1-3 
patients per month. 
Results 
Patient demographics 
One-hundred and sixteen patients were registered over 45 months starting July 2007 providing 
an average rate of accrual of 2.6 subjects per month. No patient under 21 years of age enrolled. 
Two patients were excluded because of ineligible sarcoma sub-type (extraskeletal myxoid 
chondrosarcoma) on central pathology review, 2 were ineligible because of use of prohibited 
concomitant medication, and 3 chose not to start therapy after registration. Characteristics for the 
109 patients who started dasatinib are shown in table 1. Chordoma and CS were the commonest 
sub-types studied. All surviving patients who started dasatinib have completed 5 years of follow-
up since enrollment. 
Dasatinib treatment and safety 
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As of June 2016, all patients are off treatment. A median of 4 cycles (range 1-87 months) of 
dasatinib were administered. Median numbers of cycles completed by patients with ASPS was 
7.5, chordoma was 6, CS was 4, ES was 9  and SFT was 2. Treatment interruption was reported 
in 62 patients (57%) and reduction in dose was reported in 36 patients (33%). Reduction in 
dasatinib dose was more frequent in patients with SFT (52%) than ES (14%), ASPS (17%), CS 
(27%) or chordoma (34%). Most patients discontinued dasatinib because of sarcoma progression. 
Hematologic adverse events were infrequent (see table 2). Non-hematologic adverse events 
occurring in more than 5% of patients included fatigue, fever, anorexia, weight loss, rash, 
nausea, vomiting, constipation, diarrhea, edema, pleural effusion, dyspnea, cough, headache, 
pain, elevated serum creatinine, hyperglycemia and hyponatremia.  Grade 3 and 4 adverse events 
were reported in 46 and 8 patients, respectively. Grade 3 adverse events occurring in at least 5% 
of patients included pain in 17%, dyspnea in 11%, pleural effusion in 6% and diarrhea in 5%. 
Non-hematologic grade 4 adverse events included 1 episode each of cardiac infarction, 
intracranial hemorrhage, meningitis, pyelonephritis, dyspnea, elevated serum creatinine and 
hypokalemia. Six patients died during therapy; 2 deaths were from general progression of 
sarcoma, 3 were related to pulmonary complications from sarcoma and 1 death was unrelated to 
sarcoma or dasatinib. The mean and median pre-treatment corrected QT intervals were 421 and 
422 milliseconds, respectively. After 4 weeks of dasatinib, the mean and median corrected QT 
intervals were not significantly different from baseline and measured 429 and 427 milliseconds, 
respectively, in 93 patients for which data was available. 
Dasatinib activity 
The 6-month PFS rate was 48%. Median PFS and OS were 5.8 months and 21.6 months, 
respectively (Fig. 1). The median PFS was 2 months for SFT, 5.5 months for CS, 6.3 months for 
chordoma, 7.9 months for ES and 11 months for ASPS. The 6-month PFS and 2-year and 5-year 
OS rates by subtype are shown in table 3. Duration of dasatinib therapy by patient is shown in 
figure 2. One patient with ASPS, 3 with chordoma and 3 with CS remained on treatment for 
more than 2 years. One patient with ASPS, 6 with CS, 6 with chordoma, 2 with ES and 5 with 
SFT had objective tumor response per Choi criteria. Of the patients with response, 19 started 
treatment with dastinib 70 mg twice daily and 1 with 100 mg twice daily. On post hoc analysis, 1 
patient with chordoma had a RECIST objective response. 
Discussion 
SARC conducted a unique clinical trial focused on patients with locally advanced or metastatic 
sarcomas in sub-types that usually exhibit an indolent rate of growth and for which there are very 
limited accepted standard chemotherapy treatments. Collectively, ASPS, ES and SFT comprise 
about 1% of soft tissue sarcomas and chordoma represents about 5% of bone sarcomas.
19
 
Because of the rarity of the different sub-types, patients were enrolled into one cohort rather than 
“indolent” histology sub-type-specific cohorts. This study demonstrated that SARC, as a 
cooperative clinical research group, was able to enroll patients with very rare sub-types at a rate 
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consistent with a priori expectations and successfully complete accrual. SARC members are 
predominately medical oncologists, with expertise in treatment of patients with sarcoma and 
commitment to sarcoma clinical research, practicing at medical centers with demonstrated multi-
disciplinary management of sarcoma patients. Most of the SARC associated members see a high 
volume of sarcoma patients and function as regional or national experts in the management of 
sarcoma which likely contributed to the successful enrollment. In addition, most of the member 
institutions support pathologists with special expertise in diagnosis of soft tissue and bone 
tumors which accounted for a low rate (<2%) of discrepancy in diagnosis between local and 
central pathologists. 
Prior to the start of this trial, very few objective responses had been reported in clinical trials of 
chemotherapy or tyrosine kinase inhibitor therapy in patients with ASPS, chordoma or SFT, and 
to our knowledge, results of prospective clinical trials of chemotherapy in patients with ES or 
chondrosarcoma had not been reported. Because of a lack of objective responses observed in 
previous trials, we used 6-month PFS rate as an estimate of dasatinib activity in this trial. 
Previous drug studies in patients with ASPS, chordoma or SFT demonstrated 6-month PFS rates 
of 50% or higher using RECIST.
8, 9, 20
 Therefore, we set the primary goal for preliminary 
evidence of dasatinib activity as a 6-month PFS rate of at least 50%. Dasatinib treatment resulted 
in a 6-month PFS rate of 48% in the group of patients enrolled in this phase II trial. One reason 
for the relatively low 6-month PFS rate is the use of Choi criteria rather than RECIST; disease 
progression per Choi occurs when tumor growth is at least 10% and thus earlier than with 
RECIST that requires a 20% increase in tumor size for progression. A minority of patients met 
criteria for sarcoma progression per RECIST; 1 patient with ASPS, 3 with chordoma, 13 with 
chondrosarcoma, 1 with ES and 8 with SFT had RECIST progressive disease. This trial would 
likely have had a 6-month PFS rate over 50% if RECIST had been used to assess tumor response 
and thus been viewed as a trial with a positive primary endpoint. Differential activity of dasatinib 
within and/or variability in natural growth rates of sarcoma sub-types also likely impacted PFS. 
Patients with SFT experienced the shortest median PFS and lowest 6-month PFS rate; whereas, 
patients with ASPS, chordoma or epithelioid sarcoma had a 6-month PFS rate of more than 50%. 
If the study had been designed to enroll patients into sub-type specific cohorts, dasatinib may 
have been declared potentially active in ASPS, chordoma and epithelioid sarcoma. Patients with 
ASPS had a relatively long median PFS and OS compared to many of the other sub-types, but 
only 1 objective response from treatment with dasatinib was observed. In comparison, recent 
trials using sunitinib or cediranib in patients with advanced ASPS demonstrated RECIST 
objective responses in more than 30% and lack of progression for at least 6 months in more than 
80% of patients (Table 4).
5, 6
 A randomized trial of cediranib versus sunitinib (NCT01391962) 
that is in progress should help to define a standard therapy for advanced/metastatic ASPS. 
Preclinical studies suggest the tyrosine kinase Src plays a role in chondrosarcoma pathogenesis, 
and dasatinib had anti-tumor activity in pre-clinical chondrosarcoma models.
13, 14
 In our study, 
patients with low or intermediate-grade CS of bone had a median PFS of 5.5 months and 6-
Page 8 of 17Cancer










month PFS rate of 47%. Six patients had an objective tumor response and 4 patients (12%) had 
stable disease on treatment for more than a year suggesting a small subset of patients may have 
had some tumor control with dasatinib. Prospective trials of drug therapy in metastatic CS have 
infrequently been conducted to provide a basis for comparison of results. In a phase II trial of the 
hedgehog pathway inhibitor, GDC-0449, in patients with progressive, advanced CS, no objective 
tumor responses were observed and the 6-month PFS rate was only 28%.
21
 Eighty-seven percent 
of patients had grade 1 or 2 chondrosarcoma, 11% had dedifferentiated chondrosarcoma and 1 
patient had clear cell chondrosarcoma in the trial of GDC-0449. The median OS in the GDC-
0449 trial was 12 months compared to 27 months in our study of dasatinib. Our preliminary 
clinical data from dasatinib treatment of CS patients along with absence of a standard effective 
drug therapy for this group of patients supports further study of dasatinib in CS. 
Chordomas express platelet-derived growth factor receptor-alpha and epidermal growth factor 
receptor and have been the subject of clinical trial research using tyrosine kinase inhibitors. 
Treatment of 56 patients with advanced chordoma using imatinib in a phase II trial demonstrated 
1 objective partial response by RECIST, 6-month PFS rate of 64% and median PFS of 9 
months.
9
 Similar results were noted in a retrospective case series analysis in 48 patients treated 
with imatinib.
22
 The authors also noted that 16.5% of the patients remained on treatment with 
stable disease for more than 18 months. In a phase II trial of lapatinib treatment of patients with 
advanced, EGFR-positive chordoma, no objective responses per RECIST were seen, but 33% of 
patients had partial response per Choi response criteria and the median PFS was 6 months.
23
 In 
our trial of dasatinib using Choi response criteria, the median PFS and 6-month PFS rate in 
patients with chordoma were 6.3 months and 54%, respectively, which are not substantially 
different from results using imatinib or lapatinib. Moreover, 14% of patients treated with 
dasatinib were surviving without tumor progression for more than 2 years and 18% of patients 
were alive at 5 years highlighting the very indolent course of disease that is seen in a subset of 
patients. 
The groups of patients with ES or SFT had the lowest survival rates in our study. The 6-month 
survival rates were remarkably similar among the histologic sub-types ranging from 71% in ES 
to 88% in conventional chondrosarcoma; however, the 2-year and 5-year survival rates in ES 
were 21% and 0%, respectively, compared with survival rates in conventional chondrosarcoma 
of 56% and 9%, respectively. Similar poor survival rates in metastatic ES were reported in an 
analysis of cases in the Surveillance, Epidemiology and End Results database.
24
 Doxorubicin-
based regimens and gemcitabine combined with docetaxel have limited activity in ES and more 
effective drugs are needed.
25, 26
 Response of SFT to dasatinib was worse than in previous reports 
of treatment with temozolomide and bevacizumab or sunitinib using Choi response criteria.
7, 8
 
Treatment with either regimen resulted in objective partial responses in about 50% of patients, 
median PFS of at least 50% and 6-month PFS rate of at least 50% compared to a median PFS of 
2 months and 6-month PFS rate of 30% with dasatinib. 
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In summary, SARC conducted a single-arm trial of dasatinib in patients with rare sarcoma sub-
types in which there is an unmet medical need for more effective chemotherapy to manage 
locally advanced or metastatic disease and was able to meet the anticipated enrollment rate and 
accrual goal for a trial of very rare cancers through a collaborative effort. Adverse events 
experienced by patients were similar in type and rate to events previously reported.
16
  Although 
the 6-month PFS rate fell short of the 50% goal for the group using Choi response criteria more 
than 50% of patients with ASPS or ES were free from disease progression more than 6 months, 
and 50% of the ASPS patients were alive for at least 2 years after enrollment. In addition, about 
15% of patients with chordoma or CS had objective tumor response and a few had stable disease 
for more than 2 years on treatment. Dasatinib should not be used as standard treatment of SFT 
but may be worth comparative study with cediranib or sunitinib depending on results in the 
ongoing ASPS trial. The low rate of OS in patients with ES highlights the urgent need to identify 
active drugs to treat patients with metastatic ES. Because of a lack of defined drug therapy for 
treatment of patients with locally-advanced, unresectable or metastatic CS of bone or chordoma 
and results discussed above, further evaluation of dasatinib in CS and chordoma should be 
considered in future clinical trials. 
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Figure 1. Kaplan-Meier progression-free survival (PFS) and overall survival (OS) curves of 
patients. 
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Table 1. Patient characteristics 
Age at registration – median (range) in years 54 (22 – 87) 
Sex – male/female 76/33 
Race 
   white 
   black 
   Asian 
   other 






   alveolar soft part sarcoma 
   chondrosarcoma 
   chordoma 
   epithelioid sarcoma 
   solitary fibrous tumor 






Prior drug therapy 
   alveolar soft part sarcoma 
   chondrosarcoma 
   chordoma 
   epithelioid sarcoma 








Table 2. Number of patients with hematologic toxicity from dasatinib 
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 
Hemoglobin 10 8 4 0 
Leukocytes 2 3 1 0 
Lymphopenia 1 2 1 0 
Neutrophils 1 1 1 2 
Platelets 5 0 2 0 
 
Table 3. Survival according to sarcoma sub-type 
Sarcoma sub-type 6-month PFS 2-year OS 5-year OS 
alveolar soft part sarcoma 62% 50% 30% 
chondrosarcoma 47% 56% 9% 
chordoma 54% 43%   18% 
epithelioid sarcoma 57% 21% 0% 
solitary fibrous tumor 30% 34% 8% 
PFS: progression-free survival; OS: overall survival 
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Table 4. Comparison of reported patient outcomes in selected phase II and retrospective sarcoma 
studies. 
 











ASPS Dasatinib 12 8% 62% 11 mo 0% ND ND 
 Sunitinib
5
 9 NR NR NR 56% 88% 17 mo 
 Cediranib
6
 43 NR NR NR 35% 84% NR 






39 NR NR NR 0% 28% 3.5 mo 
Chordoma Dasatinib 32 19% 54% 6.3 mo 0% ND ND 
 Imatinib
9
 50 NR NR NR 2% 66% 9.2 mo 
 Imatinib
22
 46 NR NR NR 0% 65% 9.9 mo 
 Lapatinib
23
 18 33% 50% 6 mo 0% 60% 8 mo 
SFT Dasatinib 25 20% 30% 2 mo 0% ND ND 
 Sunitinib
8
 31 48% NR 7 mo 6% 45% 6 mo 
 TMZ/BEV
7
 14 79% 79% 9.7 mo 14% 93% 10.8 mo 
  
Abbreviations:  ASPS, alveolar soft part sarcoma; CS, chondrosarcoma; SFT, solitary fibrous tumor; PTS, 
patients; ORR, objective response rate; mo, month; PFS, progression-free survival; ND, not done; NR, 
not reported; TMZ/BEV, temozolomide and bevacizumab. 
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Figure 1. Kaplan-Meier progression-free and overall survival curves.  
 
30x22mm (600 x 600 DPI)  
Page 16 of 17Cancer













Figure 2. Time on treatment with dasatinib by sarcoma sub-type.  
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